Submitted:
21 November 2024
Posted:
22 November 2024
You are already at the latest version
Abstract
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.
Keywords:
1. Introduction
2. Material and Methods
3. Results
4. Discussion
5. Conclusion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pencegahan Dan Pengendalian Mpox (Monkeypox); Kementerian Kesehatan RI: Jakarta, 2023. [Google Scholar]
- Mitjà, O.; Alemany, A.; Marks, M.; Lezama Mora, J. I.; Rodríguez-Aldama, J. C.; Torres Silva, M. S.; Corral Herrera, E. A.; Crabtree-Ramirez, B.; Blanco, J. L.; Girometti, N.; et al. Mpox in People with Advanced HIV Infection: A Global Case Series. The Lancet, 2023, 401 (10380), 939–949. [CrossRef]
- World Health Organization. Mpox (monkeypox) outbreak https://www.who.int/europe/emergencies/situations/monkeypox (accessed , 2024). 16 May.
- World Health Organizations. Multi-Country Outbreak of Mpox: External Situation Report 32; 2024.
- Kannan, S.; Ali, P. S. S.; Sheeza, A. Monkeypox: Epidemiology, Mode of Transmission, Clinical Features, Genetic Clades and Molecular Properties. Eur Rev Med Pharmacol Sci, 2022, 26 (16), 5983–5990.
- Minhaj, F. S.; Ogale, Y. P.; Whitehill, F.; Schultz, J.; Foote, M.; Davidson, W.; Hughes, C. M.; Wilkins, K.; Bachmann, L.; Chatelain, R.; et al. Monkeypox Outbreak - Nine States, 22. MMWR Morb Mortal Wkly Rep, 2022, 71 (23), 764–769. 20 May. [CrossRef]
- Sharma, A.; Prasad, H.; Kaeley, N.; Bondalapati, A.; Edara, L.; Kumar, Y. A. Monkeypox Epidemiology, Clinical Presentation, and Transmission: A Systematic Review. Int J Emerg Med, 2023, 16 (1), 20. [CrossRef]
- Yinka-Ogunleye, A.; Dalhat, M.; Akinpelu, A.; Aruna, O.; Garba, F.; Ahmad, A.; Adeleye, A.; Botson, I.; Oluwafemi, B.; Ogunbode, O.; et al. Mpox (Monkeypox) Risk and Mortality Associated with HIV Infection: A National Case-Control Study in Nigeria. BMJ Glob Health, 2023, 8 (11). [CrossRef]
- Ghazy, R. M.; Elrewany, E.; Gebreal, A.; ElMakhzangy, R.; Fadl, N.; Elbanna, E. H.; Tolba, M. M.; Hammad, E. M.; Youssef, N.; Abosheaishaa, H.; et al. Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine. Vaccines, 11(11), 1708. [CrossRef]
- Pischel, L.; Martini, B. A.; Yu, N.; Cacesse, D.; Tracy, M.; Kharbanda, K.; Ahmed, N.; Patel, K. M.; Grimshaw, A. A.; Malik, A. A.; et al. Vaccine Effectiveness of 3rd Generation Mpox Vaccines Against Mpox and Disease Severity: A Systematic Review and Meta-analysis. Vaccine, 2024, 42(25), 126053. [CrossRef]
- Deputy, N. P.; Deckert, J.; Chard, A. N.; Sandberg, N.; Moulia, D. L.; Barkley, E.; Dalton, A. F.; Sweet, C.; Cohn, A. C.; Little, D. R.; et al. Vaccine Effectiveness of JYNNEOS Against Mpox Disease in the United States. New England Journal of Medicine, 2023, 388(26), 2434–2443. [CrossRef]
- Sinto, R.; Johan, A.; Nilasari, H.; Yunihastuti, E.; Nelwan, E. J. Mpox Skin Lesion. Acta Med Indones-Indones J Intern Med •, 2024, 56.
- Thornhill, J. P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L. B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M. S.; et al. Monkeypox Virus Infection in Humans across 16 Countries April-22. N Engl J Med, 2022, 387 (8), 679–691. 20 June. [CrossRef]
- Fink, D. L.; Callaby, H.; Luintel, A.; Beynon, W.; Bond, H.; Lim, E. Y.; Gkrania-Klotsas, E.; Heskin, J.; Bracchi, M.; Rathish, B.; et al. Clinical Features and Management of Individuals Admitted to Hospital with Monkeypox and Associated Complications across the UK: A Retrospective Cohort Study. Lancet Infect Dis, 2023, 23 (5), 589–597. [CrossRef]
- Mailhe, M.; Beaumont, A. L.; Thy, M.; Le Pluart, D.; Perrineau, S.; Houhou-Fidouh, N.; Deconinck, L.; Bertin, C.; Ferré, V. M.; Cortier, M.; et al. Clinical Characteristics of Ambulatory and Hospitalized Patients with Monkeypox Virus Infection: An Observational Cohort Study. Clinical Microbiology and Infection, 2023, 29 (2), 233–239. [CrossRef]
- Hoffmann, C.; Jessen, H.; Wyen, C.; Grunwald, S.; Noe, S.; Teichmann, J.; Krauss, A. S.; Kolarikal, H.; Scholten, S.; Schuler, C.; et al. Clinical Characteristics of Monkeypox Virus Infections among Men with and without HIV: A Large Outbreak Cohort in Germany. HIV Med, 2023, 24 (4), 389–397. [CrossRef]
- Ogoina, D.; Dalhat, M. M.; Denue, B. A.; Okowa, M.; Chika-Igwenyi, N. M.; Yusuff, H. A.; Christian, U. C.; Adekanmbi, O.; Ojimba, A. O.; Aremu, J. T.; et al. Clinical Characteristics and Predictors of Human Mpox Outcome during the 2022 Outbreak in Nigeria: A Cohort Study. Lancet Infect Dis, 2023, 23 (12), 1418–1428. [CrossRef]
- Dou, X.; Li, F.; Ren, Z.; Zhang, D.; Li, J.; Li, D.; Sun, Y.; Jin, H.; Li, R.; Li, W.; et al. Clinical, Epidemiological, and Virological Features of Mpox in Beijing, China - -June 21, 2023. Emerg Microbes Infect, 2023, 12 (2), 2254407. 31 May. [CrossRef]
- Wang, X.; Lun, W. Skin Manifestation of Human Monkeypox. J Clin Med, 2023, 12 (3). [CrossRef]
- Tarín-Vicente, E. J.; Alemany, A.; Agud-Dios, M.; Ubals, M.; Suñer, C.; Antón, A.; Arando, M.; Arroyo-Andrés, J.; Calderón-Lozano, L.; Casañ, C.; et al. Clinical Presentation and Virological Assessment of Confirmed Human Monkeypox Virus Cases in Spain: A Prospective Observational Cohort Study. The Lancet, 2022, 400 (10353), 661–669. [CrossRef]
- Corma-Gómez, A.; Cabello, A.; Orviz, E.; Morante-Ruiz, M.; Ayerdi, O.; Al-Hayani, A.; Muñoz-Gómez, A.; Santos, I. D. L.; Gómez-Ayerbe, C.; Rodrigo, D.; et al. Long or Complicated Mpox in Patients with Uncontrolled HIV Infection. J Med Virol, 2024, 96 (3). [CrossRef]
- Laporan Penilaian Risiko Cepat Mpox di Indonesia Tahun 2024; Kementerian Kesehatan RI: Jakarta, 2024.



| Characteristics | Number of Participants (n = 59) | HIV | non-HIV (n = 13) | |
|---|---|---|---|---|
| Received ART (n = 39) | Without ART (n = 4) | |||
| Assigned Sex at Birth | ||||
| Male | 59 (100%) | 39 (100%) | 4 (100%) | 13 (100%) |
| Female | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Age in Years | Mean: 30.34 (21-49, SD 5.310) | |||
| 18-24 | 7 (11.9%) | 4 (10.3%) | 2 (50%) | 1 (7.7%) |
| 25-29 | 21 (35.6%) | 15 (38%) | 1 (25%) | 4 (30.8%) |
| 30-39 | 29 (49.2%) | 18 (46%) | 1 (25%) | 8 (61.5%) |
| 40-49 | 2 (3.4%) | 2 (5%) | 0 (0%) | 0 (0%) |
| Sexual Orientation | ||||
| MSM | 45 (76.3%) | 34 (87%) | 3 (75%) | 6 (46.2%) |
| Bisexual | 9 (15.3%) | 3 (8%) | 1 (25%) | 4 (30.8%) |
| Heterosexual | 4 (6.8%) | 2 (5%) | 0 (0%) | 2 (15.4%) |
| Unknown | 1 (1.7%) | 0 (0%) | 0 (0%) | 1 (1.7%) |
| Occupation | ||||
| Sex worker | 3 (5.1%) | 3 (8%) | 0 (0%) | 0 (0%) |
| Other | 53 (89.8%) | 33 (85%) | 4 (100%) | 13 (100%) |
| Unknown | 3 (5.1%) | 3 (8%) | 0 (0%) | 0 (0%) |
| Total CD4 (cells/mm3) | ||||
| <200 | 6 (13%) | 3 (8%) | 3 (75%) | |
| 200-500 | 8 (17.4%) | 8 (21%) | 0 (0%) | |
| >500 | 4 (8.7%) | 4 (10%) | 0 (0%) | |
| Unknown | 28 (60.9%) | 24 (61.5%) | 1 (25%) | |
| Viral Load | ||||
| >40 | 1 (2%) | 1 (3%) | 0 (0%) | |
| Undetected | 20 (43.5%) | 20 (51.3%) | 0 (0%) | |
| Unknown | 25 (54.3%) | 18 (46.2%) | 4 (100%) | |
| Clinical Manifestations | Number of Participants (n = 59) | HIV | non-HIV (n = 13) | |
|---|---|---|---|---|
| Received ART (n = 39) | Without ART (n = 4) | |||
| Skin Lesion | 55 (93.2%) | 36 (92%) | 4 (100%) | 13 (100%) |
| Site of Lesion | ||||
| Face | 38 (64.4%) | 25 (64%) | 4 (100%) | 7 (53.8%) |
| Lower extremities | 26 (44.1%) | 15 (38%) | 3 (75%) | 7 (53.8%) |
| Palm | 25 (42.4%) | 15 (38%) | 3 (75%) | 7 (53.8%) |
| Genital | 21 (35.6%) | 14 (36%) | 1 (25%) | 6 (46.2%) |
| Chest | 20 (33.9%) | 14 (36%) | 3 (75%) | 2 (15.4%) |
| Body | 16 (27.1%) | 9 (23%) | 2 (50%) | 5 (38.5%) |
| Perianal | 12 (20.3%) | 8 (21%) | 2 (50%) | 2 (15.4%) |
| Foot | 9 (15.3%) | 6 (15%) | 0 (0%) | 3 (23.1%) |
| Perioral | 7 (11.9%) | 4 (10%) | 2 (50%) | 1 (7.7%) |
| Other | 19 (32.2%) | 11 (28%) | 2 (50%) | 6 (46.2%) |
| Lesion morphology | ||||
| Vesicle | 31 (52.5%) | 22 (56%) | 2 (50%) | 6 (46.2%) |
| Pustule | 29 (49.2%) | 23 (59%) | 0 (0%) | 5 (38.5%) |
| Necrotic Lesion | 18 (30.5%) | 10 (26%) | 4 (100%) | 3 (23.1%) |
| Papule | 18 (30.5%) | 12 (31%) | 1 (25%) | 4 (30.8%) |
| Umbilicated Pustule | 10 (16.9%) | 6 (15%) | 2 (50%) | 2 (15.4%) |
| Ulcer | 6 (10.2%) | 3 (8%) | 2 (50%) | 1 (7.7%) |
| Macule | 4 (6.8%) | 3 (8%) | 0 (0%) | 1 (7.7%) |
| Other | 2 (3.4%) | 1 (3%) | 1 (25%) | 0 (0%) |
| Number of Lesion | ||||
| <25 (Benign) | 37 (62.7%) | 25 (64%) | 0 (0%) | 10 (76.9%) |
| 25-99 (Medium) | 11 (18.6%) | 7 (18%) | 2 (50%) | 2 (15.4%) |
| > 250 (Very Severe) | 2 (3.4%) | 1 (3%) | 1 (25%) | 0 (0%) |
| Unknown | 9 (15.3%) | 6 (15.4%) | 1(25%) | 1 (7.7%) |
| Pain in lesion | 32 (54.2%) | 21 (53.8%) | 2 (50%) | 8 (61.5%) |
| Lesion pruritus | 3 (5.1%) | 1 (3%) | 1 (25%) | 1 (7.7%) |
| Fever | 48 (81.4%) | 31 (79.5%) | 4 (100%) | 11 (84.6%) |
| Rash | 39 (66.1%) | 25 (64.1%) | 3 (75%) | 10 (76.9%) |
| Lymphadenopathy | 35 (59.3%) | 23 (59%) | 2 (50%) | 9 (69.2%) |
| Inguinal | 23 (39.0%) | 15 (38%) | 1 (25%) | 6 (46.2%) |
| Cervical | 15 (25.4%) | 9 (23%) | 1 (25%) | 5 (38.5%) |
| Axilla | 3 (5.1%) | 3 (8%) | 0 (0%) | 0 (0%) |
| Other | 1 (1.7%) | 1 (3%) | 0 (0%) | 0 (0%) |
| Sore throat | 25 (42.4%) | 15 (38.5%) | 1 (25%) | 7 (53.8%) |
| Myalgia | 23 (39.0%) | 14 (36%) | 2 (50%) | 6 (46.2%) |
| Shiver | 19 (32.2%) | 11 (28%) | 1 (25%) | 6 (46.2%) |
| Anogenital pain | 19 (32.2%) | 15 (38%) | 1 (25%) | 3 (23.1%) |
| Fatigue | 14 (23.7%) | 8 (21%) | 2 (50%) | 4 (30.8%) |
| Arthralgia | 14 (23.7%) | 10 (26%) | 1 (25%) | 2 (15.4%) |
| Swallowing pain | 15 (25.4%) | 9 (23%) | 1 (25%) | 4 (30.8%) |
| Respiratory symptoms | 13 (22.0%) | 7 (18%) | 1 (25%) | 4 (30.8%) |
| Genital inflammation | 15 (25.4.0%) | 11 (21%) | 1 (25%) | 3 (20%) |
| Asthenia | 10 (16.9%) | 6 (15%) | 0 (0%) | 3 (23.1%) |
| Backpain | 10 (16.9%) | 8 (21%) | 0 (0%) | 2 (15.4%) |
| Diarrhea | 9 (15.3%) | 4 (10%) | 0 (0%) | 5 (38.5%) |
| Nausea | 10 (16.9%) | 7 (18%) | 0 (0%) | 3 (23.1%) |
| Anogenital hemorrhage | 7 (11.9%) | 5 (13%) | 1 (25%) | 1 (1.7%) |
| Pain in mouth | 8 (13.6%) | 4 (10%) | 1 (25%) | 2 (15.4%) |
| Dysphagia | 8 (13.6%) | 4 (10%) | 0 (0%) | 3 (5.1%) |
| Vomiting | 2 (3.4%) | 2 (5%) | 0 (0%) | 0 (0%) |
| Eye redness | 3 (5.1%) | 1 (3%) | 1 (25%) | 0 (0%) |
| Others | 5 (8.5%) | 5 (13%) | 0 (0%) | 0 (0%) |
| Specimens | Number of Specimens | Positive Rate | ||
|---|---|---|---|---|
| Total | HIV | Non-HIV | ||
| Tonsilopharyngeal swab | 56 (94.9%) | 84% (47/56) | 84% (36/43) | 85% (11/13) |
| Lesion fluid | 53 (89.8%) | 96% (51/53) | 95% (38/40) | 100% (13/13) |
| Rectal swab | 34 (57.6%) | 47% (13/34) | 50% (13/26) | 38% (3/8) |
| Necrotic lesion swab | 10 (16.9%) | 100% (10/10) | 100% (9/9) | 100% (1/1) |
| Anogenital swab | 9 (15.3%) | 56% (5/9) | 50% (3/6) | 67% (2/3) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).